ArticleSensors (Basel, Switzerland)2025
GazeCapsNet: A Lightweight Gaze Estimation Framework.
Article in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Integrating skeleton based representations for robust yoga pose classification using deep learning models.Scientific reports · 2026Article
- Coarse Eyeball Direction Recognition from Eyelid Skin Deformation Using Infrared Distance Sensors on Eyewear.Sensors (Basel, Switzerland) · 2026Article
- Boosting underwater image quality: a deep learning approach to denoising and enhancement.Scientific reports · 2026Article
- PoseShot: hybrid CNN-BiLSTM transformer model for free throw action recognition via pose analysis.Scientific reports · 2026Article
- Curvelet-enhanced transformer architecture for blurred action fine-grained detection.Scientific reports · 2025Article
- A method for detecting metal surface defects using a dynamic fine-grained multi-branch encoder.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gaze estimation is increasingly pivotal in applications spanning virtual reality, augmented reality, and driver monitoring systems, necessitating efficient yet accurate models for mobile deployment. Current methodologies often fall short, particularly in mobile settings, due to their extensive computational requirements or reliance on intricate pre-processing. Addressing these limitations, we present Mobile-GazeCapsNet, an innovative gaze estimation framework that harnesses the strengths of capsule networks and integrates them with lightweight architectures such as MobileNet v2, MobileOne, and ResNet-18. This framework not only eliminates the need for facial landmark detection but also significantly enhances real-time operability on mobile devices. Through the innovative use of Self-Attention Routing, GazeCapsNet dynamically allocates computational resources, thereby improving both accuracy and efficiency. Our results demonstrate that GazeCapsNet achieves competitive performance by optimizing capsule networks for gaze estimation through Self-Attention Routing (SAR), which replaces iterative routing with a lightweight attention-based mechanism, improving computational efficiency. Our results show that GazeCapsNet achieves state-of-the-art (SOTA) performance on several benchmark datasets, including ETH-XGaze and Gaze360, achieving a mean angular error (MAE) reduction of up to 15% compared to existing models. Furthermore, the model maintains a real-time processing capability of 20 milliseconds per frame while requiring only 11.7 million parameters, making it exceptionally suitable for real-time applications in resource-constrained environments. These findings not only underscore the efficacy and practicality of GazeCapsNet but also establish a new standard for mobile gaze estimation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.